Centro Regional Integrado de Oncologia | Fortaleza, Brazil

Research site

(Unclaimed)

Location

Rua Francisco Calaca, 1300, Álvaro Weyne, Fortaleza, Ceara, Brazil

Site insights

Top conditions

Top treatments

Pembrolizumab

Platinum

Ipilimumab

INCMGA00012

Pertuzumab

Paclitaxel

Capecitabine

Carboplatin

Lapatinib

Leuprolide Acetate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 16 total trials

Locations recently updated

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)

This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast ca...

Active, not recruiting

HER2 Positive Breast Cancer

Drug: Pertuzumab

Drug: Trastuzumab

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) befor...

Active, not recruiting

Non-small Cell Lung Cancer

Drug: Placebo

Drug: Pemetrexed

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants...

Active, not recruiting

Melanoma

Renal Cell Carcinoma (RCC)

Drug: INCB 99280 with Ipilimumab

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

A Phase III, randomised, double-blind, placebo-controlled, multi-centre study to assess the efficacy of olaparib maintenance monotherapy in relapsed...

Active, not recruiting

Relapsed Ovarian Cancer

Following Complete or Partial Response to Platinum Based Chemotherapy

Drug: Placebo to match olaparib 300mg

Drug: Olaparib 300mg tablets

Locations recently updated

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (OVELIA)

This is a phase 3, single arm, open-label study evaluating the effectiveness of TOL2506 to suppress ovarian function in premenopausal women with HR+,...

Enrolling

Breast Cancer

Drug: Anastrozole Tablets

Drug: Tamoxifen

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)

The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metast...

Active, not recruiting

Metastatic Nonsquamous Non-Small Cell Lung Cancer

Metastatic Squamous Non-Small Cell Lung Cancer

Drug: Placebo

Drug: Paclitaxel

Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance t...

Active, not recruiting

Head and Neck Neoplasms

Radiation: Standard Fractionation (SFX) Radiotherapy

Biological: Pembrolizumab

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

This is a randomized, active-controlled, open-label study of pembrolizumab (Pembro) given prior to surgery and pembrolizumab in combination with stan...

Active, not recruiting

Head and Neck Neoplasms

Radiation: Radiotherapy 70 Gray/day

Biological: Pembrolizumab 200 mg